Medigene AG (MDG1.DE)
EUR 1.08
(-1.64%)
EUR 1.08
(-1.64%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 6.03 Million EUR | -80.69% |
| 2022 | 31.24 Million EUR | 198.64% |
| 2021 | 10.46 Million EUR | 19.59% |
| 2020 | 8.74 Million EUR | -17.71% |
| 2019 | 10.63 Million EUR | 37.12% |
| 2018 | 7.75 Million EUR | -31.83% |
| 2017 | 11.37 Million EUR | 16.68% |
| 2016 | 9.74 Million EUR | 43.2% |
| 2015 | 6.8 Million EUR | -50.61% |
| 2014 | 13.78 Million EUR | 81.56% |
| 2013 | 7.59 Million EUR | 20.81% |
| 2012 | 6.28 Million EUR | 34.97% |
| 2011 | 4.65 Million EUR | 103.14% |
| 2010 | 2.29 Million EUR | -94.19% |
| 2009 | 39.46 Million EUR | -0.35% |
| 2008 | 39.6 Million EUR | 65.88% |
| 2007 | 23.87 Million EUR | -23.53% |
| 2006 | 31.22 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 2.23 Million EUR | 50.71% |
| 2024 Q2 | 1.45 Million EUR | -34.9% |
| 2023 Q3 | 1.48 Million EUR | -4.19% |
| 2023 FY | 6.03 Million EUR | -80.69% |
| 2023 Q4 | 1.48 Million EUR | 0.0% |
| 2023 Q1 | 1.53 Million EUR | -48.62% |
| 2023 Q2 | 1.55 Million EUR | 1.17% |
| 2022 Q4 | 2.98 Million EUR | 0.0% |
| 2022 Q1 | 12.64 Million EUR | 104.83% |
| 2022 Q2 | 2.26 Million EUR | -82.12% |
| 2022 Q3 | 2.98 Million EUR | 31.87% |
| 2022 FY | 31.24 Million EUR | 198.64% |
| 2021 FY | 10.46 Million EUR | 19.59% |
| 2021 Q3 | 3.08 Million EUR | 33.59% |
| 2021 Q2 | 2.31 Million EUR | 7.67% |
| 2021 Q4 | 6.17 Million EUR | 100.0% |
| 2021 Q1 | 2.14 Million EUR | -50.44% |
| 2020 Q4 | 4.32 Million EUR | 100.0% |
| 2020 FY | 8.74 Million EUR | -17.71% |
| 2020 Q2 | 2.27 Million EUR | 23.71% |
| 2020 Q3 | 2.16 Million EUR | -4.73% |
| 2020 Q1 | 1.83 Million EUR | -50.2% |
| 2019 Q2 | 3.54 Million EUR | 68.88% |
| 2019 Q4 | 3.68 Million EUR | 183.04% |
| 2019 FY | 10.63 Million EUR | 37.12% |
| 2019 Q1 | 2.09 Million EUR | 949.39% |
| 2019 Q3 | 1.3 Million EUR | -63.22% |
| 2018 FY | 7.75 Million EUR | -31.83% |
| 2018 Q1 | 2.76 Million EUR | -34.13% |
| 2018 Q4 | -247 Thousand EUR | -109.88% |
| 2018 Q3 | 2.5 Million EUR | -8.56% |
| 2018 Q2 | 2.73 Million EUR | -1.16% |
| 2017 Q4 | 4.19 Million EUR | 85.71% |
| 2017 Q3 | 2.26 Million EUR | -1.95% |
| 2017 Q2 | 2.3 Million EUR | -11.61% |
| 2017 Q1 | 2.6 Million EUR | -3.26% |
| 2017 FY | 11.37 Million EUR | 16.68% |
| 2016 Q1 | 3.9 Million EUR | 163.77% |
| 2016 FY | 9.74 Million EUR | 43.2% |
| 2016 Q2 | 1.56 Million EUR | -60.07% |
| 2016 Q4 | 2.69 Million EUR | 70.48% |
| 2016 Q3 | 1.58 Million EUR | 1.35% |
| 2015 FY | 6.8 Million EUR | -50.61% |
| 2015 Q4 | 1.48 Million EUR | -24.16% |
| 2015 Q3 | 1.95 Million EUR | 15.96% |
| 2015 Q2 | 1.68 Million EUR | -0.06% |
| 2015 Q1 | 1.68 Million EUR | -68.82% |
| 2014 Q4 | 5.4 Million EUR | 136.78% |
| 2014 FY | 13.78 Million EUR | 81.56% |
| 2014 Q3 | 2.28 Million EUR | -37.63% |
| 2014 Q2 | 3.66 Million EUR | 50.7% |
| 2014 Q1 | 2.43 Million EUR | -1.66% |
| 2013 Q4 | 2.47 Million EUR | 29.17% |
| 2013 FY | 7.59 Million EUR | 20.81% |
| 2013 Q1 | 1.3 Million EUR | -14.16% |
| 2013 Q2 | 1.89 Million EUR | 45.07% |
| 2013 Q3 | 1.91 Million EUR | 0.74% |
| 2012 Q2 | 1.67 Million EUR | 3.21% |
| 2012 Q4 | 1.52 Million EUR | 4.24% |
| 2012 FY | 6.28 Million EUR | 34.97% |
| 2012 Q3 | 1.46 Million EUR | -12.6% |
| 2012 Q1 | 1.62 Million EUR | -51.14% |
| 2011 Q1 | 648 Thousand EUR | 101.96% |
| 2011 Q2 | 1.23 Million EUR | 90.28% |
| 2011 Q3 | 427 Thousand EUR | -65.37% |
| 2011 Q4 | 3.32 Million EUR | 677.52% |
| 2011 FY | 4.65 Million EUR | 103.14% |
| 2010 Q4 | -32.99 Million EUR | -426.1% |
| 2010 Q2 | 13.15 Million EUR | 9.55% |
| 2010 Q3 | 10.11 Million EUR | -23.06% |
| 2010 Q1 | 12 Million EUR | 10.17% |
| 2010 FY | 2.29 Million EUR | -94.19% |
| 2009 Q2 | 8.37 Million EUR | -19.22% |
| 2009 Q4 | 10.89 Million EUR | 27.03% |
| 2009 Q3 | 8.57 Million EUR | 2.45% |
| 2009 FY | 39.46 Million EUR | -0.35% |
| 2009 Q1 | 10.36 Million EUR | 0.0% |
| 2008 FY | 39.6 Million EUR | 65.88% |
| 2007 FY | 23.87 Million EUR | -23.53% |
| 2006 FY | 31.22 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| BioNTech SE | 3.81 Billion EUR | 99.842% |
| CureVac N.V. | 53.75 Million EUR | 88.776% |
| Biotest Aktiengesellschaft | 684.6 Million EUR | 99.119% |
| Biotest Aktiengesellschaft | 684.6 Million EUR | 99.119% |
| BRAIN Biotech AG | 55.33 Million EUR | 89.096% |
| Formycon AG | 77.69 Million EUR | 92.234% |
| Heidelberg Pharma AG | 9.85 Million EUR | 38.796% |